Immunocore Holdings plc (IMCR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Immunocore Holdings plc (IMCR) closed at USD 28.34 on 2026-10-14, a change of -16 % over the past year, with a market capitalization of USD 1.52B.

Immunocore Holdings plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Immunocore Holdings plc key figures

Previous close

USD 28.34 (2026-10-14)

1-year change

-16 %

Market cap

USD 1.52B

Enterprise value

USD 1.07B

P/E ratio (trailing)

-77.58

P/E ratio (forward)

-39.08

EPS (trailing)

-0.38

EPS (forward)

-0.75

PEG ratio

n/a

Price to book

3.61

Revenue growth

18.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

20.72

Employees

524

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Immunocore Holdings plc

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Immunocore Holdings plc and compare it with other stocks.